rabi
viru
rabv
highest
human
case
fatal
rate
viral
diseas
nearli
individu
receiv
one
avail
prophylax
postexposur
treatment
high
mortal
rate
coupl
worldwid
distribut
rabv
mean
approxim
peopl
kill
year
main
burden
born
children
develop
world
effect
pre
postexposur
vaccin
frontlin
mechan
along
control
anim
reservoir
combat
spread
viru
suscept
anim
host
vaccin
stimul
product
virusneutr
antibodi
vna
envelop
glycoprotein
gprotein
similar
immun
confer
live
viru
infect
neutral
immun
respons
rabv
direct
viral
gprotein
cox
et
al
host
immun
respons
also
includ
nonneutr
antibodi
cellmedi
immun
nucleoprotein
dietzschold
et
al
increas
monitor
humor
respons
rabv
vaccin
studi
preval
natur
rabv
lyssaviru
infect
domest
wild
speci
would
allow
specif
proportion
respons
endem
countri
howev
major
countri
resourcelimit
laboratori
routin
method
test
rabv
vna
countri
involv
high
contain
biosafeti
level
facil
thu
current
practic
undertak
thorough
sustain
surveil
screen
undertaken
major
locat
european
bat
lyssaviru
european
bat
lyssaviru
predominantli
infect
insectivor
bat
howev
rare
zoonot
event
occur
result
infect
human
sheep
stone
marten
fook
et
al
previou
work
shown
antibodi
respons
individu
vaccin
rabv
human
diploid
cell
vaccin
hdcv
abl
neutral
rabv
rabi
viru
challeng
viru
australian
bat
lyssaviru
brook
et
al
hanlon
et
al
howev
vaccin
confer
complet
protect
emerg
eurasian
lyssaviru
strain
aravan
viru
khujand
viru
irkut
viru
west
caucasian
bat
viru
hanlon
et
al
lyssavirus
belong
phylogroup
ii
badran
et
al
fook
hanlon
et
al
pseudotyp
virus
carri
genom
core
one
viru
envelop
anoth
mani
exampl
pseudotyp
use
viru
receptor
identif
cell
entri
dalgleish
et
al
woollewi
bate
viru
neutral
antibodi
bartosch
et
al
clapham
et
al
temperton
et
al
retrovir
pseudotyp
base
gammaretroviru
murin
leukemia
viru
mlv
lentiviru
human
immunodefici
viru
hiv
bear
vesicular
stomat
viru
vsv
gprotein
commonli
use
vector
gene
therapi
naldini
et
al
takeuchi
et
al
zufferey
et
al
fact
retrovir
pseudotyp
use
rabv
envelop
previous
shown
function
neurotrop
gene
vector
desmari
et
al
mazaraki
et
al
menti
et
al
previous
shown
sarscoronaviru
spike
sprotein
influenza
viru
haemagglutinin
retrovir
pseudotyp
express
envelop
protein
use
sensit
specif
assay
detect
vna
pathogen
temperton
et
al
report
analysi
neutral
antibodi
sera
rabvvaccin
human
canin
felin
use
lentivir
pseudotyp
lyssaviru
protein
present
pseudotyp
gprotein
accur
determin
precis
role
antibodi
target
protein
play
crossneutr
virusneutr
titr
correl
fulllength
gprotein
sequenc
encod
glycoprotein
power
novel
assay
detect
rabv
vna
use
pseudotyp
adapt
meet
need
mani
laboratori
worldwid
without
requir
high
contain
use
pseudotyp
luciferas
report
establish
assay
sensit
specif
serum
sampl
previous
character
use
world
health
organ
offic
intern
de
epizooti
oie
fluoresc
antibodi
viru
neutral
test
favn
human
embryon
kidney
cell
origin
refer
dubridg
et
al
use
transfect
determin
tropism
rang
pseudotyp
viru
togeth
human
glioma
cell
line
soda
et
al
babi
hamster
kidney
cell
clone
origin
obtain
american
tissu
cultur
collect
atcc
stoker
macpherson
human
rhabdomyosarcoma
cell
stratton
et
al
mous
neuroblastoma
cell
origin
obtain
atcc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
glutamax
fetal
calf
serum
fc
cell
line
cultur
dmem
fc
penicillinstreptomycin
transfect
cell
plate
h
prior
addit
complex
compris
plasmid
dna
fugen
facilit
dna
transport
cell
describ
manufactur
roch
hiv
type
gagpol
construct
zufferey
et
al
green
fluoresc
protein
gfp
report
construct
pcsgw
incorpor
egfp
cassett
driven
part
spleen
focu
form
viru
longtermin
repeat
sequenc
demaison
et
al
firefli
luciferas
report
construct
pcsflw
luciferas
gene
clone
pcsgw
place
gfp
kind
gift
dr
b
capecchi
novarti
vaccin
diagnost
siena
itali
transfect
concurr
requir
envelop
construct
ratio
respect
mlv
gagpol
construct
pcmvi
tower
et
al
gfp
report
construct
pcncg
lncx
plasmid
clontech
encod
enhanc
gfp
cmv
drive
express
rna
firefli
luciferas
report
construct
op
de
beeck
et
al
use
ratio
hiv
construct
case
cell
wash
h
posttransfect
incub
fresh
media
supernat
harvest
h
posttransfect
titrat
cell
line
remain
viru
store
fresh
frozen
pseudotyp
aliquot
use
viru
titrat
neutral
assay
respect
round
freezethaw
result
averag
loss
viru
titr
vsv
pseudotyp
see
supplementari
fig
avail
onlin
version
paper
rabv
isol
use
studi
atcc
ggene
sequenc
amplifi
use
rtpcr
titan
kit
describ
manufactur
roch
primer
design
base
publish
sequenc
genbank
access
number
isol
rv
isol
rv
ggene
sequenc
genbank
access
number
respect
subclon
exist
transfer
plasmid
use
specif
pcr
primer
set
primer
list
supplementari
tabl
pcr
introduc
uniqu
kpni
xhoi
restrict
site
end
gene
amplifi
ligat
pucbas
plasmid
incorpor
human
cytomegaloviru
immedi
earli
promot
cox
et
al
sequenc
ensur
correct
align
vsv
gprotein
indiana
serotyp
express
vector
pmdg
describ
previous
naldini
et
al
use
creat
control
pseudotyp
viru
plasmid
contain
gagpol
report
gene
transfect
cell
hiv
vsv
pseudotyp
viral
particl
purifi
sucros
cushion
remov
gprotein
incorpor
viral
envelop
separ
sdspage
cell
extract
western
blot
prepar
resuspend
cell
h
posttransfect
sdspage
load
buffer
mm
trishcl
ph
vv
glycerol
mm
vv
sd
wv
bromophenol
blue
protein
transfer
use
semidri
equip
pvdf
transfer
membran
hybondp
amersham
bioscienc
blot
primari
mous
antirabv
gprotein
monoclon
antibodi
kind
gift
merial
immunoblot
vsv
gprotein
perform
use
antivsv
gprotein
monoclon
antibodi
clone
sigma
determin
protein
loadingtransf
ident
load
gel
stain
coomassi
blue
nitrocellulos
membran
blot
two
gag
antibodi
dilut
aid
reagent
nibsc
antiactin
antibodi
abl
detect
isoform
dilut
sigma
blot
antimous
horseradish
peroxidaseconjug
igg
secondari
antibodi
dilut
amersham
bioscienc
use
prior
antibodi
bind
detect
enhanc
chemiluminesc
amersham
bioscienc
vari
sampl
compris
sera
rabvvaccin
human
dog
cat
oie
standard
refer
dog
serum
dilut
iu
stabilzym
surmod
inc
test
detail
descript
serum
given
supplementari
tabl
determin
stringenc
assay
total
serum
sampl
use
dog
negativeposit
initi
determin
favn
nine
cat
three
human
sera
addit
rabbit
serum
rais
use
crossneutr
experi
sera
titrat
use
twofold
serial
dilut
obtain
experi
undertaken
least
duplic
titr
vari
one
doubl
dilut
repeat
third
time
geometr
mean
record
keep
standard
serolog
practic
bresson
et
al
live
viru
experi
undertaken
use
favn
describ
previous
use
brook
et
al
cliquet
et
al
pseudotyp
valu
calcul
use
end
point
method
condit
pseudotyp
serial
dilut
multipl
replic
result
infect
replic
low
dilut
infect
high
dilut
infect
inocul
intermedi
dilut
dilut
viru
result
infect
replic
could
calcul
plate
pseudotyp
viru
result
output
rel
light
unit
rlu
incub
doubl
dilut
sera
h
addit
cell
incub
h
medium
remov
brightglo
reagent
promega
ad
luciferas
activ
detect
min
later
read
plate
glomax
micropl
luminomet
promega
endpoint
titr
equival
valu
chosen
use
favn
test
initi
experi
use
gfp
report
protein
analys
fluoresc
microscopi
flow
cytometri
facscan
bd
result
background
rlu
viru
alon
gfp
cell
alon
deduct
analysi
crossneutr
experi
perform
follow
mean
pseudotyp
input
rlu
determin
whether
viral
gprotein
express
envelop
pseudotyp
viru
perform
western
blot
use
supernat
transfect
cell
rabv
monoclon
antibodi
viral
particl
purifi
cell
supernat
use
sucros
cushion
ensur
secret
envelop
present
sampl
abl
detect
rabv
envelop
protein
sampl
lane
fig
rabv
gprotein
detect
three
neg
control
lane
repres
hiv
vsv
compar
level
gprotein
express
pseudotyp
particl
viral
envelop
blot
vsv
gprotein
associ
vsv
pseudotyp
particl
observ
similar
level
express
fig
subsequ
blot
membran
gag
antibodi
confirm
presenc
lentivir
particl
fig
protein
load
establish
run
ident
sd
gel
stain
coomassi
blue
fig
observ
high
compar
express
fig
vsv
gprotein
fig
fig
extract
cell
use
produc
vsv
pseudotyp
analys
actin
control
use
ensur
equal
protein
load
fig
pseudotyp
viru
prepar
made
packag
either
gfp
firefli
luciferas
report
gene
marker
infect
titrat
cell
line
known
permiss
infect
wildtyp
rabv
ie
bhk
cell
other
previous
test
luciferasepseudotyp
viru
hiv
lentivir
core
produc
higher
viral
titr
fig
mlv
gammaretrovir
core
fig
convers
gfpmlv
viru
fig
potent
gfphiv
fig
except
bhk
cell
cell
line
highli
permiss
gfp
luciferas
pseudotyp
bhk
gave
strongest
result
hivbas
pseudotyp
highest
luciferas
titr
overal
cell
appear
almost
entir
refractori
infect
permiss
mlvbase
pseudotyp
result
luciferas
gfp
viru
across
differ
cell
line
correl
except
mlv
viru
stock
bhk
cell
result
indic
hiv
vector
titrat
bhk
cell
yield
sensit
system
pseudotyp
record
approxim
gfp
pseudotyp
titr
iu
pseudotyp
iu
pseudotyp
viru
vsv
gprotein
sinc
bhk
cell
also
use
favn
assay
allow
direct
comparison
neutral
describ
order
determin
whether
incub
vari
amount
pseudotyp
antibodi
affect
titr
increas
log
pseudotyp
use
neutral
assay
oie
refer
standard
plu
mediumtitr
hightitr
sera
viru
concentr
determin
luciferas
rlu
use
input
rlu
oie
standard
posit
control
iu
could
achiev
complet
neutral
tabl
howev
input
decreas
rlu
rlu
oie
standard
abl
neutral
greater
dilut
effect
observ
use
sera
felin
anoth
canin
sampl
thu
level
virusantigen
input
increas
concomit
decreas
vna
titr
tabl
establish
work
concentr
luciferas
pseudotyp
viru
test
blind
sera
rabv
vaccin
recipi
end
point
four
doubl
dilut
initi
determin
sampl
neg
failur
iu
fig
poor
respons
gave
insuffici
protect
accord
oiewho
criteria
six
clearli
posit
sera
differ
titr
six
posit
sera
test
higher
serum
dilut
tandem
nine
posit
sampl
blind
respect
favn
neutral
titr
fig
unblind
result
mirror
obtain
use
favn
test
panel
low
medium
hightitr
rabvspecif
sera
fail
neutral
pseudotyp
bear
vsv
gprotein
data
shown
determin
sensit
pseudotyp
assay
differenti
serum
sampl
differ
neutral
titr
compar
titr
obtain
use
pseudotyp
assay
favn
titr
two
set
titr
correl
strongli
sera
high
iu
read
also
score
higher
dilut
result
tabl
data
also
show
differ
anim
speci
felin
canin
human
elicit
rang
strong
weak
vna
respons
rabv
taken
togeth
present
scatter
plot
result
obtain
reveal
high
correl
coeffici
pseudotyp
favn
titr
fig
establish
work
protocol
accur
determin
virusneutr
antibodi
adapt
assay
detect
humor
respons
pseudotyp
bear
gprotein
repres
isol
could
studi
effect
antibodi
specif
target
gprotein
alon
crossneutr
whether
anim
speci
elicit
potent
respons
other
titr
pseudotyp
viru
obtain
gprotein
pseudotyp
compar
within
titr
achiev
vsv
gprotein
fig
therefor
compar
pattern
observ
vna
respons
rabv
antisera
differ
anim
differ
lyssavirus
fig
human
serum
sampl
neutral
greatest
degre
follow
neutral
profil
observ
cat
sera
dog
neutral
three
genotyp
obviou
pattern
common
sampl
antibodi
rabbit
serum
also
neutral
three
pseudotyp
greatest
neutral
observ
nine
neutral
respons
compar
fig
correl
coeffici
fig
fig
analysi
fulllength
gprotein
amino
acid
sequenc
use
reveal
similar
degre
diverg
margin
close
relat
respect
tabl
valu
versu
versu
rank
invers
order
degre
amino
acid
divers
respect
gprotein
pseudotyp
particl
express
rabv
envelopegprotein
antigen
similar
nativ
protein
wildtyp
live
rabv
viru
particl
function
allow
particl
entri
neutral
antirabv
sera
use
antibodi
shown
previous
detect
rabv
gprotein
abl
detect
protein
immunoblot
conduct
pseudotyp
viru
antibodi
detect
gprotein
viru
lack
rabv
envelop
glycoprotein
pseudotyp
bear
either
hiv
envelop
vsv
gprotein
although
vsv
rabv
member
viru
famili
rhabdovirida
howev
use
vsvg
monoclon
antibodi
observ
margin
less
incorpor
envelop
protein
pseudotyp
level
vsv
gprotein
express
also
compar
transfect
produc
cell
suggest
gprotein
incorpor
equal
effici
pseudotyp
expect
cleav
gag
protein
predomin
matur
pseudotyp
particl
unsplic
gag
predomin
cell
use
replicationcompet
isol
highli
pathogen
virus
strictli
regul
major
countri
requir
use
categori
contain
laboratori
use
pseudotyp
technolog
construct
modifi
lentivir
vector
establish
assay
util
replicationincompet
particl
measur
rabv
vna
titr
accur
method
benefit
allow
experi
undertaken
categori
biosafeti
laboratori
sinc
pseudotyp
unabl
replic
caus
product
infect
assay
also
benefit
detect
vna
alon
contrast
elisa
similar
favn
give
accur
pictur
protect
antibodi
present
sampl
sera
variou
host
speci
evalu
neutral
antibodi
gprotein
result
show
pseudotyp
assay
specif
equal
sensit
compar
whooieapprov
favn
assay
shown
effect
differenti
posit
neg
sera
accur
reflect
vna
titr
posit
sera
report
human
sera
recipi
rabv
hdcv
crossneutr
brook
et
al
hanlon
et
al
confirm
observ
use
pseudotyp
consist
notion
gprotein
target
neutral
antibodi
lyssaviru
protein
present
pseudotyp
particl
furthermor
result
show
antibodi
serum
vaccin
anim
specif
target
gprotein
crossneutr
distinct
lyssaviru
genotyp
vari
titr
depend
viral
genotyp
anim
serum
obtain
gprotein
antibodi
respons
human
cat
higher
infect
follow
final
addit
sampl
need
test
confirm
observ
result
expect
extent
given
sampl
rabvvaccin
individu
expect
rabbit
serum
rais
neutral
genotyp
higher
dilut
crossneutr
data
versu
support
hypothesi
higher
degre
similar
gprotein
sequenc
compar
neutral
titr
brook
et
al
hanlon
et
al
lower
valu
versu
support
hypothesi
howev
eblv
higher
sequenc
ident
like
due
one
sera
use
experi
rais
rabvbas
vaccin
addit
small
sampl
size
individu
variat
may
influenc
result
illustr
difficulti
interpret
antigen
differ
use
crossneutr
data
wider
studi
use
multipl
repres
genotyp
sera
rais
multipl
genotyp
may
assist
quantifi
antigen
differ
lyssavirus
crossneutr
lentivir
pseudotyp
bear
lyssaviru
envelop
provid
opportun
analys
neutral
epitop
gprotein
quantit
qualit
method
describ
extend
lyssavirus
phylogroup
cdna
clone
plasmid
use
gener
pseudotyp
sitespecif
mutagenesi
exploit
elucid
domain
crucial
gprotein
function
effect
virion
attach
entri
neutral
epitop
determin
strainspecif
groupspecif
respons
sera
monoclon
antibodi
adopt
neutral
assay
use
either
replicationcompet
pseudotyp
virus
issu
need
address
assay
employ
routin
serolog
surveil
system
free
secret
envelop
protein
viru
prepar
adsorb
antibodi
supernat
thu
skew
neutral
test
therefor
import
standard
viru
input
order
obtain
sensit
reliabl
result
achiev
determin
concentr
viru
known
neg
serum
becom
posit
use
concentr
viru
slightli
greater
routin
use
rabi
refer
laboratori
part
assay
valid
process
altern
baselin
posit
control
avail
exampl
oie
refer
standard
rabv
neutral
assay
smallest
amount
viru
need
achiev
lowest
serum
dilut
could
determin
allow
greatest
rang
serum
dilut
test
neg
sampl
provid
fail
result
assay
result
achiev
use
viru
input
rlu
rlu
therefor
would
recommend
rlu
viru
input
neutral
assay
use
pseudotyp
background
read
cell
alon
viru
alon
rlu
luciferas
carryov
sampl
pseudotyp
produc
neg
gfp
result
rlu
depend
cell
line
use
pseudotyp
input
therefor
valu
consid
cutoff
posit
viral
titr
use
larg
volum
pseudotyp
howev
pseudotyp
viru
normal
use
viru
alon
luciferas
read
gener
larger
would
observ
therefor
use
background
valu
encourag
observ
bhk
cell
routin
use
live
viru
favn
test
highli
permiss
pseudotyp
convers
cell
readili
infect
live
lyssavirus
permiss
pseudotyp
hiv
core
contrast
mlvbase
pseudotyp
made
use
differ
report
construct
abl
infect
cell
suggest
postentri
restrict
impos
select
lentivir
report
gene
vector
could
due
specif
restrict
pcsgw
pcsflw
promot
cell
line
cell
also
almost
complet
refractori
infect
vsv
pseudotyp
produc
hiv
report
plasmid
data
shown
altern
lentivir
core
may
subject
postpenetr
restrict
cell
tower
fatal
rate
rabv
infect
human
receiv
either
pre
postexposur
prophylaxi
high
near
compar
diseas
caus
highli
pathogen
virus
ebola
viru
haemorrhag
fever
fatal
influenza
ongo
research
surveil
rabv
limit
support
suggest
rabi
neglect
diseas
especi
rabiesendem
countri
africa
asia
fook
therefor
need
readdress
balanc
increas
current
level
surveil
rabv
countri
infect
caus
high
level
mortal
would
also
help
limit
misdiagnosi
consequ
underreport
rabv
infect
mallewa
et
al
main
assay
current
use
favn
provid
good
sensit
specif
requir
handl
live
rabv
altern
assay
detect
rabv
antibodi
elisa
cliquet
et
al
rapid
fluoresc
focu
inhibit
testgfp
khawplod
et
al
design
howev
former
differenti
neutral
nonneutr
antibodi
latter
still
requir
high
containmentlevel
facil
use
pseudotyp
detect
vna
remov
need
use
live
virus
provid
high
sensit
high
specif
detect
neutral
antibodi
incorpor
gfp
luciferas
report
gene
make
assay
applic
mani
laboratori
involv
rabv
surveil
good
candid
high
throughput
screen
laboratori
lack
fluoresc
luciferas
detect
report
could
use
also
amen
test
presenc
antibodi
small
volum
sera
microassay
may
obtain
bat
conclus
report
show
possibl
analys
crossneutr
antibodi
respons
differ
lyssaviru
genotyp
use
lentivir
pseudotyp
approach
could
greatli
improv
surveil
new
emerg
lyssavirus
evalu
protect
current
vaccin
offer
pathogen
